9LB.F LEGEND BIOTECH SP.ADS/2
- Market cap
- EUR 3.38B
- P/E
- -
- P/B
- 3.16x
- ROE
- 3.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 9LB.F undervalued?
Graham numberThe Graham number of LEGEND BIOTECH SP.ADS/2 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LEGEND BIOTECH SP.ADS/2 fundamental analysis
No fundamental analysis for LEGEND BIOTECH SP.ADS/2 yet.
LEGEND BIOTECH SP.ADS/2 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LEGEND BIOTECH SP.ADS/2
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous …
Full company profileLEGEND BIOTECH SP.ADS/2 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LEGEND BIOTECH SP.ADS/2 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 68.8M | 117M | 285M | 627M | 1.03B | 1.40B |
| Gross Profit | 68.8M | 51.6M | 141M | 393M | 621M | 788M |
| Operating Income | -392M | -456M | -528M | -310M | -137M | 72.9M |
| EBITDA | - | -417M | -480M | -115M | -232M | 140M |
| Net Income | -404M | -446M | -518M | -177M | -297M | 40.8M |
| EPS | -1.31 | -1.35 | -1.42 | -0.48 | -0.80 | 0.11 |
| Balance Sheet | ||||||
| Total Assets | 1.12B | 1.33B | 1.85B | 1.67B | 1.73B | 1.68B |
| Total Liabilities | 354M | 587M | 597M | 630M | 732M | 409M |
| Shareholders' Equity | 766M | 744M | 1.25B | 1.04B | 1.00B | 1.27B |
| Cash & Short-term Investments | 689M | 786M | 1.28B | 287M | 902M | 461M |
| Cash Flow | ||||||
| Operating Cash Flow | -198M | -201M | -393M | -144M | -100M | -189M |
| Capital Expenditure | 45.4M | 22.3M | 22.7M | 14.1M | 28.6M | 27.5M |
| Free Cash Flow | -244M | -224M | -416M | -158M | -129M | -217M |
| Ratios | ||||||
| ROE | -52.7% | -60.0% | -41.4% | -17.0% | -29.6% | 3.2% |
| ROA | -36.1% | -33.5% | -28.0% | -10.6% | -17.1% | 2.4% |
| Net Profit Margin | -586.4% | -381.5% | -181.8% | -28.2% | -28.8% | 2.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LEGEND BIOTECH SP.ADS/2 dividends
LEGEND BIOTECH SP.ADS/2 has not paid dividends in the last 5 fiscal years.
Who owns LEGEND BIOTECH SP.ADS/2
- Insiders 1.90%
- Institutions 53.48%
- Public & others 44.62%
- Shares outstanding 194M
- Free float 90.8M
LEGEND BIOTECH SP.ADS/2 company profile
- Company name
- LEGEND BIOTECH SP.ADS/2
- Ticker
- 9LB.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,300
- Fiscal year end
- December
- Address
- 2101 Cottontail Lane, Somerset, NJ, United States, 08873
- Phone
- 737 317 5050
- Website
- legendbiotech.com
About LEGEND BIOTECH SP.ADS/2
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
LEGEND BIOTECH SP.ADS/2 management
6- Ms. Ingrid ZhangChief Executive Officer · born 1973
- Mr. Carlos Santos GarciaChief Financial Officer · born 1972
- Ms. Ananda Elizabeth Martin Esq., J.D.Global Compliance Officer · born 1974
- Mr. Robert StaloffGeneral Counsel
- Dr. Yuhong Qiu Ph.D.Interim Head of Research & Development and Senior VP of Regulatory Affairs
- Mr. Birk VanderweeenSenior Vice President of Global Manufacturing & Supply